AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PHIO

Plott Ronald Todd purchased $17K of PHIO

Plott Ronald Todd purchased 15,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.14 on 2026-08-19.

Original reporting
SEC EDGAR · Plott Ronald Todd
Published Aug 20, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 12:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHIO
Neutral
low confidence
Mentioned
$PHIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHIONeutralLow
01

Why it matters

The transaction is a routine insider purchase with limited market relevance.

02

Market read

Low relevance; small insider buy does not materially affect stock.

03

What to watch

Potential upcoming clinical data not reflected in this filing.

Relevance 4/10Novelty 3/10Timing: post‑market filing on Aug 20

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

$PHIONeutralLow confidence
Context

Director Plott Ronald Todd purchased 15,000 PHIO shares at $1.14 each, total $17,100.

Expected impact

Minimal impact; unlikely to move price.

Evidence & confidence

Purchase amount is tiny relative to market cap and typical trading volume.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market only.

Global

None

Counterpoint

What could challenge this read

Even a small insider purchase could precede a positive catalyst.

Key entities

  • Company
    Phio Pharmaceuticals Corp.

    Biotech firm developing therapies.

  • Individual
    Plott Ronald Todd

    Director of PHIO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHIO insider trading history →

Related articles

$PHIOMedAI 8/10

Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting

Phio Pharmaceuticals (PHIO) presented Phase 1b trial data for its cancer treatment PH-762 at the ASDS Annual Meeting. The study suggested PH-762 is well-tolerated and may offer a tissue-sparing neoadjuvant therapy for cutaneous carcinomas. A Phase 2b study is planned for 2027. According to the company, PH-762 could improve patient outcomes by shrinking tumors before surgery.

timminspress.com
$PHIOMedAI 8/10

Phio Pharmaceuticals 3Q 2026: EPS ($0.36) — 10-Q Summary

Phio Pharmaceuticals reported a wider net loss of $4.16M in 3Q 2026, up 73.9% YoY, due to increased R&D and regulatory costs. EPS was ($0.36). The company advanced PH-762 toward a Phase 2b study, with a 65% response rate in Phase 1b trials. Manufacturing of PH-762 drug substance began in 3Q 2026.

tradingview.com
$PHIOMed

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatmen

SEC EDGAR 8-K